Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients
Article
[키워드] 28-day mortality
acute respiratory syndrome
administration
adverse effects
adverse event
adverse events
antibody
antibody assay
Antibody Response
Antibody titers
Antigen
assays
binding
case-control study
CCP
Characteristics
characterization
Control
Controlled trial
convalescent
convalescent plasma
coronavirus
COVID-19
COVID-19 convalescent plasma
died
disease severity
Donor
donors
enrolled
evaluated
group
had no
heterogeneous
hospital
Hospitalized
immune response
Immunosuppressed
median
median age
Microarray
NAb
Neutralizing
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
neutralizing antibody assays
neutralizing capacity
not affect
pathogen-reduction treatment.
Patient
Pneumonia
recipient
recipients
response
responses
SARS CoV-2
SARS-CoV-2
SARS-CoV-2 antigen
SARS-CoV2
single-center
survival
symptom onset
transfused
transfusion
treated
Treatment
variable
with COVID-19
[DOI] 10.1111/trf.17083 PMC 바로가기
[DOI] 10.1111/trf.17083 PMC 바로가기